Skip to main content

Advertisement

SpringerLink
Log in

A Nonsystematic Review on Risankizumab: a Novel Drug Recently Approved for Moderate to Severe Psoriasis

  • Medicine
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

In April 2019, the USFDA has approved the humanized monoclonal antibody IgG, Risankizumab, that targets the protein p19 subunit of interleukin (IL-23), for the treatment of moderate to severe plaque psoriasis. The drug was developed by the AbbVie in collaboration with known Boehringer Ingelheim for the management similar immune-mediated inflammatory disorders like inflammatory bowel disease, rheumatic arthritis, etc. The recommended treatment in the case of plague psoriasis with Risankizumab was to begin with 2 initial doses amounts to 150 mg given at baseline (week 0) and again at week 4 that will be followed by 150 mg thereafter by 2 injections every 12 weeks. This article provides a hand on review regarding the drug with all the recent trials and indications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.

    Article  CAS  Google Scholar 

  2. Chiricozzi A, Antonioli L, Panduri S, Fornai M, Romanelli M, Blandizzi C. Risankizumab for the treatment of moderate to severe psoriasis. Expert Opin Biol Ther. 2019;19(1):1–8.

    Article  CAS  Google Scholar 

  3. Kaplon H, Reichert JM. Antibodies to watch in 2019. InMAbs. 2019;11(2):219–38.

    CAS  Google Scholar 

  4. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

    Article  Google Scholar 

  5. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.

    Article  CAS  Google Scholar 

  6. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Machado Á, Torres T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018;8:83–92.

    CAS  Google Scholar 

  8. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–24.

    Article  CAS  Google Scholar 

  9. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.

    Article  CAS  Google Scholar 

  10. Khatri A, Cheng L, Camez A, Ignatenko S, Pang Y, Othman AA. Lack of effect of 12-week treatment with risankizumab on the pharmacokinetics of cytochrome P450 probe substrates in patients with moderate to severe chronic plaque psoriasis. Clin Pharmacokinet. 2019;58(6):805–14.

    Article  Google Scholar 

  11. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US);2006. Risankizumab.[Updated 2019 May 1].

  12. Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–94.

    Article  CAS  Google Scholar 

  13. Zhang TT, Ma J, Durbin KR, Montavon T, Lacy SE, Jenkins GJ, et al. Determination of IL-23 pharmacokinetics by highly sensitive accelerator mass spectrometry and subsequent modeling to project IL-23 suppression in psoriasis patients treated with anti-IL-23 antibodies. AAPS J. 2019;21(5):82.

    Article  Google Scholar 

  14. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64:ii 65–8.

    Article  Google Scholar 

  15. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60.

    Article  CAS  Google Scholar 

  16. Blauvelt A, Papp KA, Gooderham M, Langley RG, Leonardi C, Lacour JP, et al. Risankizumab efficacy/safety in moderate-to-severe plaque psoriasis: 16-week results from immhance. Acta Dermatol Venereol. 2018;98(Supplement 219):30. https://doi.org/10.2340/00015555-2978.

    Article  Google Scholar 

  17. McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893–900.

    Article  CAS  Google Scholar 

  18. Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population pharmacokinetics of Risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019;58(10):1309–21.

    Article  CAS  Google Scholar 

  19. Khatri A, Eckert D, Oberoi R, Suleiman A, Pang Y, Cheng L, et al. Pharmacokinetics of Risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis. J Clin Pharmacol. 2019;59(12):1656–68.

    Article  CAS  Google Scholar 

  20. Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–34.

    Article  CAS  Google Scholar 

  21. Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–84.

    Article  CAS  Google Scholar 

  22. Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28(4):179–93.

    Article  Google Scholar 

  23. Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86.

    Article  CAS  Google Scholar 

Download references

Funding

Nil

Author information

Authors and Affiliations

  1. Department of Pharmacology, All India Institute of Medical sciences (AIIMS), Jodhpur, India

    Shoban Babu Varthya

  2. Department of Pharmacology, All India Institute of Medical sciences (AIIMS), Raipur, India

    Pugazhenthan Thangaraju

  3. Department of Microbiology, All India Institute of Medical sciences (AIIMS), Raipur, India

    Sajitha Venkatesan

  4. Department of Pharmacology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Karaikal, India

    A. R. Vijayakumar

  5. AKT Memorial College of Engineering and Technology, Kallakurichi, Tamil Nadu, India

    Eswaran Thangaraju

Authors
  1. Shoban Babu Varthya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pugazhenthan Thangaraju
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sajitha Venkatesan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. R. Vijayakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eswaran Thangaraju
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pugazhenthan Thangaraju.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varthya, S.B., Thangaraju, P., Venkatesan, S. et al. A Nonsystematic Review on Risankizumab: a Novel Drug Recently Approved for Moderate to Severe Psoriasis. SN Compr. Clin. Med. 2, 1174–1180 (2020). https://doi.org/10.1007/s42399-020-00356-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42399-020-00356-3

Keywords

Search

Navigation